The U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) for the treatment of people with advanced, inoperable, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) previously treated with fluoropyrimidine– and platinum-based chemotherapy. The approval came after the regulatory agency granted priority review to the application. It was based on data from the ATTRACTION-3 Phase 3 clinical trial (NCT02569242), which showed that Opdivo significantly extends survival compared with standard chemo. With this approval, Bristol Myers Squibb‘s…
You must be logged in to read/download the full post.
The post FDA Approves Opdivo for Advanced Esophageal Cancer appeared first on BioNewsFeeds.